Studies from Cardiovascular Research Foundation in the Area of Managed Care Reported (Temporal Trends in Mitral Valve Repair Procedures and Outcomes Among Older U.S. Adults): Managed Care

2026 OCT 01 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on Managed Care. According to news originating from New York City, New York, by NewsRx correspondents, research stated, “Mitral valve (MV) transcatheter edge-to-edge repair (M-TEER) has reshaped the management of mitral regurgitation in high surgical risk patients. As M-TEER adoption expands, understanding concurrent changes in procedural utilization, patient characteristics, and clinical outcomes is important.”

Our news journalists obtained a quote from the research from Cardiovascular Research Foundation, “The objective of the study was to evaluate temporal trends in procedural utilization, comorbidity burden, and mortality among Medicare beneficiaries undergoing MV repair. Medicare beneficiaries undergoing MV repair between 2017 and 2021 were analyzed. Procedure volumes, Elixhauser Comorbidity Index, and mortality at 30-days, 30-days postdischarge, 1-year, and 2-years were assessed. Temporal mortality trends were analyzed using adjusted Cox models with calendar year as a continuous variable. Among 81,215 beneficiaries, 39,097 underwent M-TEER and 42,118 surgical MV repair. M-TEER utilization increased from 15.0 to 27.6 per 100,000 beneficiaries (+84.0%), whereas surgical MV repair decreased from 29.1 to 20.7 per 100,000 (-28.9%), resulting in a 9.5% overall increase in MV repair use. The Elixhauser Comorbidity Index increased overall (+7.8%), remained stable among M-TEER patients (-0.2%), and decreased among surgical MV repair patients (-5.1%). Overall, adjusted mortality decreased at 30-days (adjusted HR [aHR]: 0.92; 95% CI: 0.89-0.94; P< 0.001), postdischarge 30-days (aHR: 0.93; 95% CI: 0.89-0.97; P< 0.001), 1-year (aHR: 0.98; 95% CI: 0.97-1.00; P = 0.013), and 2-years (aHR: 0.98; 95% CI: 0.97-0.99; P< 0.001). Between 2017 and 2021, M-TEER utilization increased substantially whereas surgical MV repair declined, resulting in increased overall MV repair utilization.”

According to the news editors, the research concluded: “Over the same period, adjusted short-term and midterm mortality improved despite a higher overall comorbidity index.”

This research has been peer-reviewed.

For more information on this research see: Temporal Trends in Mitral Valve Repair Procedures and Outcomes Among Older U.S. Adults. JACC Advances, 2026;5:103283.

The news correspondents report that additional information may be obtained from David J. Cohen, Cardiovascular Research Foundation, New York, New York, United States. Additional authors for this research include Philipp von Stein, Martin B. Leon, Alexandra Popma, Jennifer von Stein, Maria C. Alu, Bjorn Redfors, Batla Falah, Juan F. Granada, Jeffrey J. Popma and Harun Kundi.

(Our reports deliver fact-based news of research and discoveries from around the world.)